More about Abbott India Limited
Fundamentals for Abbott India Limited
Regulatory Filings for Abbott India Limited
Why Oman Is Now India's Most Strategic Trade Partner
Infrastructure Bet Fuels Cement Surge
Apollo FY26: When Healthcare Becomes a Flywheel
NITI Blueprint Could Turn Brain Drain Into $135Bn Engine
Fundamentals for Abbott India Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.
Revenue projections:
With Abbott India Limited's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.
Financial Ratios:
| currentRatio | 2.554000 |
|---|---|
| forwardPE | 28.933979 |
| debtToEquity | 3.602000 |
| earningsGrowth | 0.076000 |
| revenueGrowth | 0.065000 |
| grossMargins | 0.467050 |
| operatingMargins | 0.270120 |
| trailingEps | 730.050000 |
| forwardEps | 908.793100 |
Abbott India Limited's current ratio of 2.554 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. Abbott India Limited's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
ABBOTINDIA's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
ABBOTINDIA's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
ABBOTINDIA's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for ABBOTINDIA's financial growth.
Price projections:
Abbott India Limited's current price does not reveal any distinct risks or opportunities compared to its projections. This neutral assessment suggests stability, where investors might choose to retain their current positions until future developments warrant a reassessment.
Recommendation changes over time:
The analysts' recent buy bias for ABBOTINDIA indicates strong confidence in the stock's future performance. This could encourage more investors to view ABBOTINDIA as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
RAINMUMBAI Turns Rain Into a Financial Asset
India’s IT Sector Faces a Historic Breaking Point
How Independent Directors Failed Rs 2,500 Crore in Value